Obecabtagene autoleucel for adults with B-cell acute lymphoblastic leukemia in remission
Tests obecabtagene autoleucel in adults whose B-cell acute lymphoblastic leukemia is in remission.
Key facts
- Who runs it
- Memorial Sloan Kettering Cancer Center
- Where
- Basking Ridge, Commack, Duarte, Harrison, Middletown, Montvale, New York, Stanford, and Uniondale, United StatesSee the 9 sites
- Trial code
- Registry title
- A Study of Obecabtagene Autoleucel in People With B-cell Acute Lymphoblastic Leukemia
- Status
- Recruiting
- Phase
- Phase 2
- People taking part
- 40 people, planned
- Started
- 3 Feb 2026
- Expected to end
- Feb 2029
- Type of study
- Interventional, 2 groups
- Treatments tested
- Obecabtagene Autoleucel
- Record updated
- 20 August 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with CD19-positive B-cell acute lymphoblastic leukemia who are in complete remission with no measurable residual disease after first treatment.
- Age
- 40 years or older. People aged 30-39 can join only if they have serious other health problems or cannot tolerate chemotherapy.
- Sex
- All sexes can join.
- Disease stage
- CD19-positive B-cell ALL (Ph-negative or Ph-positive) in first MRD-negative complete remission, or complete remission with incomplete blood count recovery, within 4 months of starting treatment.
- Earlier treatment
- Must have had first-line treatment for ALL (for example HyperCVAD, asparaginase-containing chemotherapy, inotuzumab, blinatumomab or a tyrosine kinase inhibitor). Certain drugs must be stopped for a set time before cell collection.
- Biomarker or test result
- CD19 on the leukemia cells at any time since diagnosis. MRD below 10^-4 in the bone marrow.
Main reasons for not taking part
- Burkitt's leukemia or lymphoma
- Measurable disease outside the bone marrow at screening
- Uncontrolled infection
- Active HIV, hepatitis B, hepatitis C, HTLV or syphilis infection
- Recent high-dose steroids or certain cancer drugs close to cell collection
The registry criteria, word for word
Show all 19 criteriaShow less
Who can take part
- Diagnosis of CD19+ B-cell ALL; Both Ph-negative and Ph-positive are allowed; Patients with EMD must have detectable disease in the bone marrow (by flow cytometry or molecular methods) in order to follow MRD
- Patients aged ≥ 40 years at time of screening A
- Patients aged 30-39 years (at time of Screening A) are allowed in the presence of high-risk comorbidities or poor tolerability of chemotherapy (e.g. history or experienced pancreatitis with therapy, BMI ≥40kg/m2, underlying liver disease precluding safer administration of pediatric inspired regimens, any further combination of documented severe comorbidities that the investigator judges to be incompatible with administering an intensive pediatric or pediatric-inspired standard chemotherapy regimen)
- In MRD negative CR or CR with incomplete hematologic recovery (CRi) at the time of screening. MRD will be assessed by flow cytometry and/or molecular testing such as ClonoSEQ at the minimum sensitivity of 10-4 from the bone marrow. Patients with MRD <10\^-4 will be eligible
- Patients may receive more than one course of upfront induction and/or consolidation, but must be in MRD- CR/CRi at time of screening, within 4 months from initiation of treatment. The 4-month window will be measured from the first day of anti-leukemic therapy initiation (excluding steroid prophase) until the Screening A test for the trial; Frontline regimens include but are not limited to:
- HyperCVAD or mini-hyper-CVD
- Asparaginase-containing multiagent chemotherapy (e.g. CALGB10403, pediatric inspired chemo)
- Inotuzumab or blinatumomab with or without chemotherapy
- Tyrosine kinase inhibitor plus steroids, chemotherapy, or blinatumomab; Adequate organ function at time of screening A, including:
- ALT or AST ≤5x ULN and total bilirubin ≤2 (or ≤3 if history of Gilbert's syndrome or leukemic infiltration of the liver)
- Serum creatinine <2.0mg/dL
- SaO2 ≥92% on room air
- Left ventricular ejection fraction (LVEF) ≥50% within 1 month of screening; ECOG performance status 0-2; CD19 expression is required at any time since diagnosis. CD19 expression may be detected by immunohistochemistry or by flow cytometry. Patients receiving prior blinatumomab are eligible if there is no documentation of CD19-negative disease after blinatumomab; CNS1 status must be documented at time of screening by CSF assessment. Patients with prior CNS2 or CNS3 disease must be CNS1 at screening and have no residual CNS deficits or symptoms; Patients will need to adhere to institutional contraception guidelines for a minimum of 1 year; Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial
Who cannot take part
- Patients with measurable extramedullary disease at screening are excluded. Patients with prior history of extramedullary disease are allowed after documentation of disease resolution by either PET/CT scan (or CT with contrast if PET cannot be performed)
- The following medications are excluded:; Steroids: Therapeutic doses of corticosteroids (greater than 10mg daily of prednisone or its equivalent) within 7 days of leukapheresis or 72 hours prior to CAR T cell infusion; Systemic chemotherapy: Must be discontinued 7 days prior to leukapheresis or 7 days prior to starting lymphodepleting chemotherapy if used during bridging; Tyrosine kinase inhibitors: Must be discontinued 48 hours prior to apheresis and 48 hours prior to starting lymphodepleting chemotherapy, if used during bridging; Blinatumomab must be discontinued 5 days before apheresis; Inotuzumab must be discontinued 2 weeks before apheresis to allow T cell recovery
- Blinatumomab may not be used as bridging therapy following apheresis
- Patients with uncontrolled systemic fungal, bacterial, viral or other infection at time of leukapheresis or at time of CAR T cell infusion
- Positive test indicating the presence of active infection with the following pathogens: HIV, Hepatitis B (detectable Hep B DNA by PCR or Hep B surface antigen), Hepatitis C (detectable Hep C RNA by PCR), HTLV, Syphilis. The tests required will be agreed upon with the manufacturer to comply with manufacturer's regulatory and manufacturing requirements
- Burkitt's leukemia or lymphoma
Where in United States
- Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities)Basking Ridge, United StatesContact: Ioannis Kalogirou Valtis, MDTaking people
- Memorial Sloan Kettering Cancer Commack - Suffolk (Limited Protocol Activities)Commack, United StatesContact: Ioannis Kalogirou Valtis, MDTaking people
- City of Hope Cancer Center (Data collection AND Specimen Analysis)Duarte, United StatesContact: Ibrahim Aldoss, MDTaking people
- Memorial Sloan Kettering Westchester (Limited Protocol Activities)Harrison, United StatesContact: Ioannis Kalogirou Valtis, MDTaking people
- Memorial Sloan Kettering Monmouth (Limited Protocol Activities)Middletown, United StatesContact: Ioannis Kalogirou Valtis, MDTaking people
- Memorial Sloan Kettering Bergen (Limited Protocol Activities)Montvale, United StatesContact: Ioannis Kalogirou Valtis, MDTaking people
- Memorial Sloan Kettering Cancer Center (All Protocol Activities)New York, United StatesContact: Ioannis Kalogirou Valtis, MDTaking people
- Stanford University (Data Collection AND Specimen Analysis)Stanford, United StatesContact: Lori Muffly, MDTaking people
- Memorial Sloan Kettering Nassau (Limited Protocol Activities)Uniondale, United StatesContact: Ioannis Kalogirou Valtis, MDTaking people
About the trial
What the trial wants to find out
The researchers are doing this study to find out whether obecabtagene autoleucel (obe-cel) is an effective treatment for people with B-cell acute lymphoblastic leukemia (ALL) that is in complete remission (CR, meaning all signs of cancer are gone) with no measurable residual disease (MRD-negative, meaning there are no detectable cancer cells). Participants in this study will have received past treatment for their B-cell ALL, and their disease will be in MRD-negative CR for the first time (first MRD-negative CR).
The 2 groups in the trial
- Cohort ATreatment being tested
will enroll Philadelphia chromosome negative patients
Treatment: Obecabtagene Autoleucel
- Cohort BTreatment being tested
is an exploratory cohort that will enroll Philadelphia chromosome positive patients
Treatment: Obecabtagene Autoleucel
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorSaves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Phase II Trial of Obecabtagene Autoleucel Consolidation in Adult Patients With Acute Lymphoblastic Leukemia in First Complete Remission Without Measurable Residual Disease
- Plain-language title
- Obecabtagene autoleucel for adults with B-cell acute lymphoblastic leukemia in remissionGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 20 August 2026